Abstract
Background: Hypogonadotropic hypogonadism (HH) is hypogonadism due to either hypothalamic or pituitary dysfunction. While gonadotropin-releasing hormone (GnRH) can directly test pituitary function, no specific test of hypothalamic function exists. Kisspeptin-54 (KP54) is a neuropeptide that directly stimulates hypothalamic GnRH release and thus could be used to specifically interrogate hypothalamic function. Congenital HH (CHH) is typically due to variants in genes that control hypothalamic GnRH neuronal migration or function. Thus, we investigated whether KP54 could accurately identify hypothalamic dysfunction in men with CHH. Methods: Men with CHH (n = 21) and healthy eugonadal men (n = 21) received an intravenous bolus of either GnRH (100 μg) or KP54 (6.4 nmol/kg), on 2 occasions, and were monitored for 6 h after administration of each neuropeptide. Results: Maximal luteinizing hormone (LH) rise after KP54 was significantly greater in healthy men (12.5 iU/L) than in men with CHH (0.4 iU/L; p < 0.0001). KP54 more accurately differentiated CHH men from healthy men than GnRH (area under receiver operating characteristic curve KP54: 1.0, 95% CI 1.0–1.0; GnRH: 0.88, 95% CI 0.76–0.99). Indeed, all CHH men had an LH rise <2.0 iU/L following KP54, whereas all healthy men had an LH rise >4.0 iU/L. Anosmic men with CHH (i.e., Kallmann syndrome) had even lower LH rises after KP54 than did normosmic men with CHH (p = 0.017). Likewise, men identified to have pathogenic/likely pathogenic variants in CHH genes had even lower LH rises after KP54 than other men with CHH (p = 0.035). Conclusion: KP54 fully discriminated men with CHH from healthy men. Thus, KP54 could be used to specifically interrogate hypothalamic GnRH neuronal function in patients with CHH.
References
1.
Adulwahid
NA
, Armar
NA
, Morris
DV
, Adams
J
, Jacobs
HS
. Diagnostic tests with luteinising hormone releasing hormone should be abandoned
. BMJ
. 1985
;291
(6507
):1471
–2
. .2.
Boehm
U
, Bouloux
PM
, Dattani
MT
, de Roux
N
, Dodé
C
, Dunkel
L
, Expert consensus document: European consensus statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment
. Nat Rev Endocrinol
. 2015 Sep
;11
(9
):547
–64
.3.
de Roux
N
, Genin
E
, Carel
JC
, Matsuda
F
, Chaussain
JL
, Milgrom
E
. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54
. Proc Natl Acad Sci USA
. 2003
;100
(19
):10972
–6
. .4.
Seminara
SB
, Messager
S
, Chatzidaki
EE
, Thresher
RR
, Acierno
JS
, Shagoury
JK
, The GPR54 gene as a regulator of puberty
. N Engl J Med
. 2003
;349
(17
):1614
–27
. .5.
Abbara
A
, Ratnasabapathy
R
, Jayasena
CN
, Dhillo
WS
. The effects of kisspeptin on gonadotropin release in non-human mammals
. Adv Exp Med Biol
. 2013
;784
:63
. .6.
Jayasena
CN
, Nijher
GM
, Chaudhri
OB
, Murphy
KG
, Ranger
A
, Lim
A
, Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis
. J Clin Endocrinol Metab
. 2009
;94
(11
):4315
. .7.
Chan
YM
, Butler
JP
, Pinnell
NE
, Pralong
FP
, Crowley
WF
, Ren
C
, Kisspeptin resets the hypothalamic GnRH clock in men
. J Clin Endocrinol Metab
. 2011
;96
(6
):E908
–15
. .8.
Chan
YM
, Butler
JP
, Sidhoum
VF
, Pinnell
NE
, Seminara
SB
. Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle
. J Clin Endocrinol Metab
. 2012
;97
(8
):E1458
–67
. .9.
Dhillo
WS
, Chaudhri
OB
, Patterson
M
, Thompson
EL
, Murphy
KG
, Badman
MK
, Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males
. J Clin Endocrinol Metab
. 2005
;90
(12
):6609
–15
. .10.
Seminara
SB
, Hayes
FJ
, Crowley
WF
Jr. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann’s syndrome): Pathophysiological and genetic considerations
. Endocr Rev
. 1998Oct
;19
(5):521
–39
.11.
Chan
YM
, Lippincott
MF
, Butler
JP
, Sidhoum
VF
, Li
CX
, Plummer
L
, Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism
. J Clin Endocrinol Metab
. 2014
;99
(12
):E2762
. .12.
Lippincott
MF
, Chan
YM
, Delaney
A
, Rivera-Morales
D
, Butler
JP
, Seminara
SB
. Kisspeptin responsiveness signals emergence of reproductive endocrine activity: implications for human puberty
. J Clin Endocrinol Metab
. 2016
;101
(8
):3061
–9
. .13.
De Tassigny
XDA
, Jayasena
C
, Murphy
KG
, Dhillo
WS
, Colledge
WH
. Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo
. PLoS One
. 2017 May 2
;12
(5
):e0176821
.14.
Jayasena
CN
, Abbara
A
, Comninos
AN
, Nijher
GM
, Christopoulos
G
, Narayanaswamy
S
, Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization
. J Clin Invest
. 2014
;124
(8
):3667
–77
. .15.
Abbara
A
, Jayasena
CN
, Christopoulos
G
, Narayanaswamy
S
, Izzi-Engbeaya
C
, Nijher
GM
, Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy
. J Clin Endocrinol Metab
. 2015
;100
(9
):3322
–31
. .16.
Dhillo
WS
, Chaudhri
OB
, Thompson
EL
, Murphy
KG
, Patterson
M
, Ramachandran
R
, Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women
. J Clin Endocrinol Metab
. 2007
;92
(10
):3958
–66
. .17.
Lippincott
MF
, Nguyen
K
, Delaney
A
, Chan
Y-M
, Seminara
SB
. Assessing sex steroid influence on kisspeptin responsiveness in idiopathic hypogonadotropic hypogonadism
. J Endocr Soc
. 2018 Sep 20
;2
(11
):1293
–305
.18.
Cassatella
D
, Howard
SR
, Acierno
JS
, Xu
C
, Papadakis
GE
, Santoni
FA
, Congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty have distinct genetic architectures
. Eur J Endocrinol
. Apr. 2018
;178
(4
):377
–88
. .19.
Richards
S
, Aziz
N
, Bale
S
, Bick
D
, Das
S
, Gastier-Foster
J
, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology
. Genet Med
. May 2015
;17
(5
):405
–24
.20.
Pitteloud
N
, Acierno
JS
, Meysing
A
, Eliseenkova
AV
, Ma
J
, Ibrahimi
OA
, Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism
. Proc Natl Acad Sci USA
. 2006
;103
(16
):6281
–6
. .21.
Comninos
AN
, Wall
MB
, Demetriou
L
, Shah
AJ
, Clarke
SA
, Narayanaswamy
S
, Kisspeptin modulates sexual and emotional brain processing in humans
. J Clin Invest
. 2017
;127
(2
):709
. .22.
Jayasena
CN
, Abbara
A
, Narayanaswamy
S
, Comninos
AN
, Ratnasabapathy
R
, Bassett
P
, Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men
. Hum Reprod
. 2015
;30
(8
):1934
.23.
George
JT
, Veldhuis
JD
, Roseweir
AK
, Newton
CL
, Faccenda
E
, Millar
RP
, Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
. J Clin Endocrinol Metab
. 2011
;96
(8
):E1228
–36
. .24.
Han
SK
, Gottsch
ML
, Lee
KJ
, Popa
SM
, Smith
JT
, Jakawich
SK
, Activation of gonadotropin-releasing hormone neurons by kisspeptin as a neuroendocrine switch for the onset of puberty
. J Neurosci
. 2005
;25
(49
):11349
–56
. .25.
Abbara
A
, Eng
PC
, Phylactou
M
, Clarke
SA
, Richardson
R
, Sykes
CM
, Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders
. J Clin Invest
. 2020
;130
(12
):6739
–53
.26.
George
JT
, Millar
RP
, Anderson
RA
. Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes
. Neuroendocrinology
. 2010
;91
(4
):302
–7
. .27.
Sykiotis
GP
, Pitteloud
N
, Seminara
SB
, Kaiser
UB
, Crowley
WF
. Deciphering genetic disease in the genomic era: The model of GnRH deficiency
. Sci Transl Med
. 2010
;2
(32
):32rv2
. .28.
Cariboni
A
, Davidson
K
, Rakic
S
, Maggi
R
, Parnavelas
JG
, Ruhrberg
C
. Defective gonadotropin-releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2: implications for the aetiology of hypogonadotropic hypogonadism
. Hum Mol Genet
. 2011
;20
(2
):336
–44
. .29.
Quinton
R
, Duke
VM
, Robertson
A
, Kirk
JM
, Matfin
G
, de Zoysa
PA
, Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization
. Clin Endocrinol
. 2001
;55
(2
):163
.30.
Bonomi
M
, Vezzoli
V
, Krausz
C
, Guizzardi
F
, Vezzani
S
, Simoni
M
, Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH)
. Eur J Endocrinol
. 2018
;178
(1
):23
. .31.
Chan
Y-M
, Lippincott
MF
, Kusa
TO
, Seminara
SB
. Divergent responses to kisspeptin in children with delayed puberty
. JCI Insight
. 2018
;3
(8
):e99109
.© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
